Guidelines

The UKMS produces guidelines relating to the diagnosis, investigation and treatment of multiple myeloma.

The UKMS produces guidelines relating to the diagnosis, investigation and treatment of multiple myeloma.

They are published in association with the British Society for Haematology (BSH) and published in the British Journal of Haematology. The Chair of the UKMS Guidelines Group is a co-opted member of the BSH Haemato-oncology Task Force, which oversees the production of all BSH guidelines relating to the haematological malignancies. The writing groups of our guidelines contain members of the UKMS Executive Committee and other experts in the disease. 

 In a rapidly moving field such as the management of multiple myeloma, it is a challenge to ensure that our guidelines are up to date. They are consequently reviewed at regular intervals, and archived when they are felt to be obsolete. The UKMS Executive feels strongly that our treatment-related guidelines should recommend the best available licensed therapies, and not be affected by what treatments are funded by the NHS at the time the guidelines are written.

We believe that the UKMS/BSH myeloma guidelines are improved as a result of the close collaboration of the group with Myeloma UK to ensure that they are ‘patient-focussed.

Chair. Dr Simon Stern

Consultant Haematologist

Epsom and St Helier University Hospitals NHS Trust.

Secretary: Dr Kevin Boyd

Consultant Haematologist

Royal Marsden NHS Foundation Trust .

Annual Report

BSH UKMS Guidelines